Psychedelics Are Placeholders for More Traditional Depression Therapies: Analysts

Psychedelics may become an important option for treatment resistant depression, but William Blair analysts expect they will likely be complemented or replaced by more traditional therapies once they are broadly available. The piece frames esketamine (Spravato) as the current on market option for TRD and notes that while it is effective and has grown commercially, its real world use is burdensome due to administration and required monitoring. It also points to concerns from analyst review that efficacy may decline from Phase 2 to Phase 3, affecting how broadly clinicians and patients will adopt psychedelic approaches. The article links these expectations to the broader depression pipeline: it compares psychedelic programs such as COMP360 and other partners in TRD and MDD, and then highlights non psychedelic or more conventional alternatives (including drug candidates in neuropsychiatry) that may capture market share if psychedelics remain limited by safety or treatment regimen constraints.